<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00068510</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000327711</org_study_id>
    <secondary_id>UCLA-0304053</secondary_id>
    <nct_id>NCT00068510</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Malignant Glioma</brief_title>
  <official_title>Phase I Dose Escalation Study of Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Malignant Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may make&#xD;
      the body build an immune response to kill tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in&#xD;
      treating patients with malignant glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the dose-limiting toxicity and maximum tolerated dose of autologous tumor&#xD;
           lysate-pulsed dendritic cells in patients with malignant gliomas.&#xD;
&#xD;
        -  Determine survival, tumor progression, and cellular immune response in patients treated&#xD;
           with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients undergo leukapheresis for the collection of peripheral blood mononuclear cells&#xD;
      (PBMC). Autologous dendritic cells (DC) are prepared from autologous PBMC exposed to&#xD;
      sargramostim (GM-CSF) and interleukin-4 and pulsed with autologous tumor lysate. Patients&#xD;
      receive autologous tumor lysate-pulsed DC intradermally on days 0, 14, and 28 in the absence&#xD;
      of unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 6-12 patients receive escalating doses of autologous tumor lysate-pulsed DC until&#xD;
      the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that&#xD;
      at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed every 2 months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-18 patients will be accrued for this study within 9-18&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to tumor progression, overall survival and cellular immune responses in brain tumor patients injected with tumor lysate pulsed dendritic cells</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>autologous tumor lysate-pulsed DC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous dendritic cells</intervention_name>
    <arm_group_label>autologous tumor lysate-pulsed DC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of one of the following malignant gliomas:&#xD;
&#xD;
          -  Anaplastic astrocytoma&#xD;
&#xD;
          -  Glioblastoma multiforme&#xD;
&#xD;
          -  Anaplastic oligodendroglioma&#xD;
&#xD;
          -  Malignant mixed oligoastrocytoma&#xD;
&#xD;
          -  WHO grade III or IV disease&#xD;
&#xD;
          -  Newly diagnosed disease&#xD;
&#xD;
          -  Bidimensionally measurable disease by contrast-enhancing MRI&#xD;
&#xD;
          -  Surgically accessible tumor for which resection is indicated&#xD;
&#xD;
          -  Previously treated with or plan to undergo treatment with conventional external beam&#xD;
             radiotherapy&#xD;
&#xD;
          -  Age 18 and over&#xD;
&#xD;
          -  Performance status Karnofsky 60-100%&#xD;
&#xD;
          -  Life expectancy at least 8 weeks&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  SGOT and SGPT no greater than 2 times normal&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2 times normal&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  Hepatitis B negative&#xD;
&#xD;
          -  Hepatitis C negative&#xD;
&#xD;
          -  BUN no greater than 1.5 times normal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times normal&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Syphilis serology negative&#xD;
&#xD;
          -  Afebrile&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  At least 2 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered.&#xD;
&#xD;
          -  At least 2 weeks since prior corticosteroids&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  More than 72 hours since prior systemic antibiotics&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  active infection&#xD;
&#xD;
          -  immunodeficiency&#xD;
&#xD;
          -  autoimmune disease that may be exacerbated by immunotherapy, including any of the&#xD;
             following:&#xD;
&#xD;
          -  Rheumatoid arthritis&#xD;
&#xD;
          -  Systemic lupus erythematosus&#xD;
&#xD;
          -  Vasculitis&#xD;
&#xD;
          -  Polymyositis-dermatomyositis&#xD;
&#xD;
          -  Scleroderma&#xD;
&#xD;
          -  Multiple sclerosis&#xD;
&#xD;
          -  Juvenile-onset insulin-dependent diabetes&#xD;
&#xD;
          -  allergy to study agents&#xD;
&#xD;
          -  pregnant or nursing&#xD;
&#xD;
          -  underlying condition that would contraindicate study therapy&#xD;
&#xD;
          -  concurrent severe or unstable medical condition that would preclude giving informed&#xD;
             consent&#xD;
&#xD;
          -  psychiatric condition that would preclude study participation or giving informed&#xD;
             consent&#xD;
&#xD;
          -  other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer, localized prostate cancer, or carcinoma in situ of the&#xD;
             cervix&#xD;
&#xD;
          -  concurrent chemotherapy during and for 2 weeks after administration of study vaccine&#xD;
&#xD;
          -  concurrent corticosteroids prior organ allograft&#xD;
&#xD;
          -  antihistamine therapy within 5 days before or after administration of study vaccine&#xD;
&#xD;
          -  other concurrent investigational agents&#xD;
&#xD;
          -  concurrent adjuvant therapy during and for 2 weeks after administration of study&#xD;
             vaccine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda M. Liau, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005 Aug 1;11(15):5515-25.</citation>
    <PMID>16061868</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>September 10, 2003</study_first_submitted>
  <study_first_submitted_qc>September 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2003</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult brain tumor</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

